Drug Class: DPP-4 Inhibitor (Dipeptidyl Peptidase-4 Inhibitor) / Gliptin | Form: Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Tagip 25mg Tablet? Tagip 25mg contains Sitagliptin Phosphate Monohydrate at the lowest available 25mg strength — specifically indicated for patients with severe kidney impairment including those on dialysis where Sitagliptin accumulates most significantly without dose reduction. Since Sitagliptin is predominantly renally eliminated, severely reduced kidney clearance causes dangerous drug accumulation at standard doses — making this carefully dose-adjusted 25mg strength essential for maintaining safe yet effective blood sugar management in the most renally compromised diabetic patients. Despite the substantially lower dose, Sitagliptin's DPP-4 inhibitory mechanism remains active — providing meaningful glucose-dependent blood sugar control while keeping drug exposure within a safe range for severely impaired kidneys. This strength requires the closest medical supervision of all Sitagliptin doses.
What is Tagip 25mg Used For?
- Type 2 diabetes with severe kidney impairment — most conservative dose-adjusted glycaemic control (گردوں کی شدید کمزوری میں ذیابیطس ٹائپ 2 کا محفوظ علاج)
- Type 2 diabetes in patients on haemodialysis or peritoneal dialysis — under strict nephrologist and diabetologist supervision
- Combination therapy where other antidiabetic medicines are contraindicated or poorly tolerated in severe renal disease
- Type 2 diabetes management in end-stage kidney disease where hypoglycaemia risk minimisation is critically important (گردوں کی آخری سٹیج میں بلڈ شوگر کا محفوظ کنٹرول)
How Does it Work? Sitagliptin selectively inhibits DPP-4 enzyme — preventing breakdown of GLP-1 and GIP incretin hormones that naturally regulate blood glucose after meals. Even at 25mg meaningful DPP-4 inhibition is achieved — stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon from alpha cells when blood sugar is elevated. This glucose-dependent mechanism is particularly valuable in severe kidney disease where hypoglycaemia risk from other antidiabetic medicines is greatly amplified — Sitagliptin's inherent safety profile regarding hypoglycaemia makes it one of the few antidiabetic options remaining viable at this stage of kidney disease when many other glucose-lowering medicines become contraindicated.
Dosage and Administration
⚠️ This is the lowest Sitagliptin dose — never reduce further without specialist nephrologist guidance. Monitor kidney function and blood glucose very regularly. Report any severe persistent abdominal pain immediately — pancreatitis risk. Can be taken with or without food. Dialysis patients may take dose without regard to dialysis timing.
| Indication | Usual Dose | Frequency | Notes |
|---|---|---|---|
| Severe kidney impairment (GFR below 30ml/min) | 25mg | Once daily | Strict nephrologist supervision required |
| End-stage renal disease on haemodialysis | 25mg | Once daily | Can be taken without regard to dialysis timing |
| End-stage renal disease on peritoneal dialysis | 25mg | Once daily | Under specialist supervision |
| Combination therapy in severe renal disease | 25mg | Once daily | Most other antidiabetics require review or cessation |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Sitagliptin Phosphate Monohydrate | 25mg (as Sitagliptin) |
Who Should NOT Take Tagip 25mg?
- Allergy to Sitagliptin or any DPP-4 inhibitor
- Type 1 diabetes mellitus — not indicated for Type 1 diabetes
- Diabetic ketoacidosis — requires urgent insulin therapy regardless of kidney function
- History of pancreatitis — Sitagliptin associated with increased pancreatitis risk
- Pregnancy and breastfeeding — insulin remains preferred treatment during pregnancy
- Children under 18 years — safety not established at any Sitagliptin dose
Side Effects
Common: Mild upper respiratory symptoms — runny nose and sore throat (ناک بہنا اور گلے کا درد), mild headache, mild nausea — very well tolerated at this lowest dose; side effect profile remains favourable even in severely renally impaired patients.
Serious — Stop and seek emergency help immediately: Acute pancreatitis — severe persistent upper abdominal pain radiating to back with nausea and vomiting (پیٹ میں شدید درد — فوری ہسپتال جائیں), severe allergic reaction — sudden widespread rash, swelling of face or throat, difficulty breathing (فوری ہسپتال جائیں), severe skin reactions — Stevens-Johnson syndrome with widespread blistering and peeling (فوری مدد لیں), significant disabling joint pain — severe arthralgia (جوڑوں کا شدید درد — ڈاکٹر کو بتائیں), worsening heart failure — sudden breathlessness with severe ankle swelling (فوری مدد لیں), hypoglycaemia when combined with insulin or sulphonylurea (بلڈ شوگر کا گرنا — فوری میٹھا کھائیں).
Drug Interactions
| Medicine | Interaction |
|---|---|
| Insulin | Increased hypoglycaemia risk in severe kidney disease — insulin dose requires very careful adjustment under specialist supervision |
| Sulphonylureas (Glibenclamide, Glimepiride) | Significantly increased hypoglycaemia risk — sulphonylureas generally avoided or used at very low doses in severe kidney impairment |
| Metformin | Metformin is generally contraindicated in severe kidney impairment — consult diabetologist before combining with Tagip 25mg |
| Digoxin | Sitagliptin slightly increases Digoxin levels — monitor carefully in kidney disease where Digoxin also accumulates |
| Cyclosporine | Increases Sitagliptin blood levels — monitor closely for increased side effects |
| Corticosteroids (Prednisolone) | Raise blood glucose — significantly impair Sitagliptin effectiveness; monitor blood sugar very closely |
| Beta-blockers | Mask hypoglycaemia warning signs — particularly important concern when combined with insulin in kidney disease |
| Alcohol (شراب) | Unpredictable blood sugar effects — avoid completely in severe kidney disease |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: Why is Sitagliptin one of the few antidiabetic medicines that can still be used in severe kidney disease? Most oral antidiabetics are contraindicated or require complete cessation in severe kidney impairment — Metformin carries lactic acidosis risk, sulphonylureas accumulate causing dangerous hypoglycaemia, and SGLT2 inhibitors lose effectiveness. Sitagliptin's glucose-dependent mechanism minimises hypoglycaemia risk and its dose can be safely adjusted down to 25mg — making it one of the few viable oral antidiabetic options remaining available at this advanced stage of kidney disease.
Q: Can Tagip 25mg be taken on dialysis days at the same time as always? Yes — Sitagliptin 25mg can be taken without regard to dialysis session timing. It is not significantly removed by haemodialysis — allowing consistent once-daily dosing regardless of whether the patient is on a dialysis day or not. Your nephrologist and diabetologist will confirm the optimal timing for your individual treatment schedule.
Q: How does severe kidney disease affect blood sugar management overall beyond just the Sitagliptin dose? Severe kidney disease significantly complicates diabetes management — kidneys normally contribute to glucose regulation and drug elimination. Many antidiabetics must be stopped, insulin requirements change unpredictably, and hypoglycaemia risk increases substantially. Close collaboration between your nephrologist and diabetologist is essential to safely manage blood sugar at this stage — Tagip 25mg is one component of a comprehensive specialist-managed treatment approach.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.